Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
Arnon Cohen, MD, MPH, PhD
Clalit Health Services
Tel Aviv, Israel
IPC Councilor
PUBLICATION
COMMENTARY
In a study published in The Lancet Rheumatology, a research group led by Catherine Smith from St John’s Institute of Dermatology described humoral and cellular immunity against SARS-CoV-2 spike glycoprotein in sixty-seven patients with psoriasis as compared to fifteen healthy controls after the second dose of the COVID-19 vaccine BNT162b2 (Pfizer-BioNTech). Patients included in the study received methotrexate (n=14), TNF inhibitors (n=19), IL-17 inhibitors (n=14), or IL-23 inhibitors (n=20). The median age was 44 years, with 52% males and 87% of White ethnicity. The study demonstrated that functional humoral immunity was not impaired by methotrexate or biologics, as observed that after the second dose of vaccine, as both patients and controls had neutralizing antibodies against wild-type SARS-CoV-2 and two variants. However, 38% of 13 participants on methotrexate and 26% of 50 participants on targeted biologics did not have detectable T-cell responses following the second dose of vaccine. There was no difference in the magnitude of T-cell responses between patients receiving methotrexate (median cytokine-secreting cells per 10⁶ cells 160, targeted biologics (169), and controls (185).
The observations on antibody development after COVID-19 vaccination in patients treated with methotrexate or targeted immunosuppressive agents are reassuring. However, the observation of absence of boosting of T-cell responses might indicate that durable cellular and humoral immunity may be impaired in some of the patients receiving these drugs.
Implications
Limitations
Limitations of the study are that patients with psoriasis not receiving immunosuppressants were not included, and that most participants were of White ethnicity. As the number of patients included and study and the duration of follow-up are limited, it is possible that differences may become statistically significant with a larger sample size or with longer follow-up.
Categories
Recent Posts
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)
Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Juul van den Reek, MD, PhD
Also Read
Psoriasis and the Pandemic: Lessons Learned from PsoProtect
The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.
Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast
A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.
Opportunities and Limitations of Telemedicine in the Diagnosis and Treatment of Psoriasis
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Subscribe to the IPC Newsletter